IL290458B1 - פורמולציות חיסון לצ'יקונגוניה - Google Patents
פורמולציות חיסון לצ'יקונגוניהInfo
- Publication number
- IL290458B1 IL290458B1 IL290458A IL29045822A IL290458B1 IL 290458 B1 IL290458 B1 IL 290458B1 IL 290458 A IL290458 A IL 290458A IL 29045822 A IL29045822 A IL 29045822A IL 290458 B1 IL290458 B1 IL 290458B1
- Authority
- IL
- Israel
- Prior art keywords
- chikv
- seq
- virus
- formulation
- concentration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19190999 | 2019-08-09 | ||
| PCT/EP2020/072435 WO2021028406A1 (en) | 2019-08-09 | 2020-08-10 | Chikungunya vaccine formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL290458A IL290458A (he) | 2022-04-01 |
| IL290458B1 true IL290458B1 (he) | 2025-02-01 |
| IL290458B2 IL290458B2 (he) | 2025-06-01 |
Family
ID=67587625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL290458A IL290458B2 (he) | 2019-08-09 | 2020-08-10 | פורמולציות חיסון לצ'יקונגוניה |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220288185A1 (he) |
| EP (1) | EP4010015A1 (he) |
| KR (1) | KR20220045154A (he) |
| AU (1) | AU2020327602A1 (he) |
| BR (1) | BR112022002082A2 (he) |
| CA (1) | CA3149919A1 (he) |
| IL (1) | IL290458B2 (he) |
| MX (1) | MX2022001430A (he) |
| PH (1) | PH12021553186A1 (he) |
| WO (1) | WO2021028406A1 (he) |
| ZA (1) | ZA202202574B (he) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998013065A1 (en) * | 1996-09-26 | 1998-04-02 | Merck & Co., Inc. | Rotavirus vaccine formulations |
| US20170014502A1 (en) * | 2015-07-16 | 2017-01-19 | Bharat Biotech International Limited | Vaccine compositions |
| WO2017172643A1 (en) * | 2016-03-31 | 2017-10-05 | Takeda Vaccines, Inc. | Compositions and methods for stabilizing alphaviruses with improved formulations |
| WO2019057793A1 (en) * | 2017-09-21 | 2019-03-28 | Valneva Se | PROCESS FOR THE PRODUCTION OF PHARMACEUTICAL COMPOSITIONS COMPRISING THE IMMUNOGENIC VIRUS OF CHIKUNGUNYA CHIKV-DELTA5NSP3 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6949027B2 (ja) | 2015-12-23 | 2021-10-20 | バルネバ オーストリア ジーエムビーエイチ | ジカウイルスワクチン |
-
2020
- 2020-08-10 IL IL290458A patent/IL290458B2/he unknown
- 2020-08-10 KR KR1020227004009A patent/KR20220045154A/ko active Pending
- 2020-08-10 AU AU2020327602A patent/AU2020327602A1/en active Pending
- 2020-08-10 BR BR112022002082A patent/BR112022002082A2/pt active IP Right Grant
- 2020-08-10 PH PH1/2021/553186A patent/PH12021553186A1/en unknown
- 2020-08-10 MX MX2022001430A patent/MX2022001430A/es unknown
- 2020-08-10 CA CA3149919A patent/CA3149919A1/en active Pending
- 2020-08-10 EP EP20764001.2A patent/EP4010015A1/en active Pending
- 2020-08-10 WO PCT/EP2020/072435 patent/WO2021028406A1/en not_active Ceased
- 2020-08-10 US US17/632,943 patent/US20220288185A1/en active Pending
-
2022
- 2022-03-02 ZA ZA2022/02574A patent/ZA202202574B/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998013065A1 (en) * | 1996-09-26 | 1998-04-02 | Merck & Co., Inc. | Rotavirus vaccine formulations |
| US20170014502A1 (en) * | 2015-07-16 | 2017-01-19 | Bharat Biotech International Limited | Vaccine compositions |
| WO2017172643A1 (en) * | 2016-03-31 | 2017-10-05 | Takeda Vaccines, Inc. | Compositions and methods for stabilizing alphaviruses with improved formulations |
| WO2019057793A1 (en) * | 2017-09-21 | 2019-03-28 | Valneva Se | PROCESS FOR THE PRODUCTION OF PHARMACEUTICAL COMPOSITIONS COMPRISING THE IMMUNOGENIC VIRUS OF CHIKUNGUNYA CHIKV-DELTA5NSP3 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4010015A1 (en) | 2022-06-15 |
| AU2020327602A1 (en) | 2022-01-27 |
| CA3149919A1 (en) | 2021-02-18 |
| US20220288185A1 (en) | 2022-09-15 |
| KR20220045154A (ko) | 2022-04-12 |
| IL290458B2 (he) | 2025-06-01 |
| WO2021028406A1 (en) | 2021-02-18 |
| PH12021553186A1 (en) | 2022-12-12 |
| MX2022001430A (es) | 2022-02-22 |
| BR112022002082A2 (pt) | 2022-04-12 |
| ZA202202574B (en) | 2023-07-26 |
| IL290458A (he) | 2022-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kaur et al. | COVID-19 Vaccine: A comprehensive status report | |
| ES2908304T3 (es) | Dosis unitaria de vacuna contra el dengue y administración de la misma | |
| AU2013295014B2 (en) | Vaccine compositions | |
| TW202144570A (zh) | 去最佳化(DEOPTIMIZED)SARS-CoV-2及其方法及用途 | |
| JP6968070B2 (ja) | 弱毒四価デングワクチンを調製するプロセス | |
| US10849943B2 (en) | Vaccine compositions comprising an attenuated mutant Zika virus | |
| CN105473603B (zh) | 用于登革病毒疫苗的方法与组合物 | |
| EP3193922B1 (en) | Vaccine | |
| US9975923B2 (en) | Methods and compositions for norovirus blockade epitopes | |
| US20210401983A1 (en) | Arthrogenic alphavirus vaccine | |
| US20220313810A1 (en) | Single shot chikungunya virus vaccine | |
| US20190177373A1 (en) | Genomic sequences encoding for an attenuated mutant zika virus | |
| US20220288185A1 (en) | Chikungunya vaccine formulations | |
| WO2014083194A1 (en) | Methods for inducing antibodies | |
| Vainionpää | COVID-19 vaccination | |
| WO2023250055A1 (en) | Immunogenic compositions for herpes simplex virus proteins | |
| WO2020229581A1 (en) | Methods for inducing a safe immune response against polio virus | |
| CN103182081A (zh) | 一种人用狂犬疫苗的制备 |